Rapid Infusion of Rituximab in a Heterogenous Pediatric Population

Legeay, Clément; Spiesser-Robelet, Laurence; Bittencourt, Henrique; Haddad, Élie; Therrien, Roxane

doi:10.1097/mph.0000000000000480

Cited by 3 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They examined 80 rituximab infusions in 22 patients and found a total adverse event rate of 2.5%. Legeay et al 21 reported a 2.7% incidence in 17 patients who received a total of 37 infusions. Bernhardt et al 7 noted a higher incidence of adverse events (10%); however, these events were categorized as low grade, and there were no dose-limiting, infusion-related adverse events.…”

Section: Discussionmentioning

confidence: 98%

“…The safety profile of rapid rituximab found within our institution is similar to that of other reports. Our institution's protocol calls for the administration of rituximab during the course of 90 minutes in a titrated manner similar to that described by Legeay et al 21 and Bernhardt et al 7 Bernhardt et al 7 were also the first to report the use of rapid-infusion rituximab in pediatric rheumatologic patients, which was given as a 120-minute infusion as opposed to 90 minutes. In the report by Wallace et al, 20 rituximab was administered during the course of 60 minutes in patients with non-malignant conditions.…”

Section: Discussionmentioning

confidence: 99%

“…The estimated infusion time saved of 57 minutes was lower than expected and lower than the approximate 2 hours per infusion that has been reported by other pediatric institutions. 20,21 However, infusion time saved was defined differently among institutions. The low amount of time saved per this report may be attributed to the method in which we estimated saved infusion time.…”

Section: Discussionmentioning

confidence: 99%

“…5,6,[8][9][10][11][12][13][14][15][16][17][18][19] The use of rapid-infusion rituximab in pediatrics was first reported by Wallace and colleagues 20 in patients with non-malignant conditions. Soon after, Legeay et al 21 reported their findings regarding the safety of rapid-infusion rituximab in a heterogeneous pediatric patient population. Most recently, the first prospective study of rapid rituximab infusion in pediatric patients with hematologic, oncologic, and rheumatologic disorders was published.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Rapid-Infusion Rituximab in a Pediatric Population

Gaffney¹,

Dahl²,

Stanton³

et al. 2020

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

OBJECTIVES The use of rapid rituximab infusion in certain pediatric populations has generally been regarded as safe. The safety of our institution's rapid rituximab protocol was evaluated. METHODS The primary end point was the number of and severity of adverse drug reactions. Secondary end points included a description of the patient population defined by the indication, dose, and number of rituximab infusions administered. Additionally, the difference in infusion times in hours of those receiving rapid rituximab infusions versus the theoretical infusion time of subsequent administration rate schedules was defined. RESULTS A total of 88 infusions for 22 patients were reviewed. No dose-limiting adverse reactions were observed. Three patients experienced grade 1 isolated infusion-related adverse events during a single infusion encounter. Two of the three patients received additional doses of rapid rituximab infusions without incident, whereas the other patient no longer required rituximab therapy. CONCLUSIONS The use of a 90-minute rituximab infusion protocol in pediatric patients with non-rheumatic diseases was well tolerated.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rapid-Infusion Rituximab in a Pediatric Population

Gaffney¹,

Dahl²,

Stanton³

et al. 2020

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The incidence of infusion‐related reactions during rapid infusion administration is comparable to standard infusion rates in patients who successfully tolerate their first infusion . Limited reports of rapid infusions in small numbers of children with autoimmune hemolytic anemia (AIHA), chronic immune thrombocytopenia (ITP), and following hematopoietic stem cell transplant demonstrate similar safety and efficacy data as seen in adult studies . There are no published prospective data specifically evaluating rapid infusions of rituximab in children with hematologic, oncologic, or rheumatologic indications.…”

Section: Introductionmentioning

confidence: 99%

Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders

Bernhardt

Guzman

Grimes

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorders, and to determine the incidence of rate-related infusion reactions. Twenty patients enrolled in the study. All patients tolerated the rapid infusion of rituximab and no patient had an infusionrelated reaction. We conclude that rapid infusions of rituximab are well tolerated and safe in our pilot group of patients.

show abstract

Rituximab

2016

Reactions Weekly

View full text Add to dashboard Cite

Rituximab Various toxicities: 11 case reportsA study to assess safety and feasibility of rapid infusion of rituximab identified eleven patients [5 male and 6 female], aged 0.6-23 years, who developed various toxicities during treatment with rituximab [route and outcomes not stated].A 2-year-old boy, who had EBV-associated lymphoproliferative disorder received 2 doses at (1 st at standard rate and 2 nd at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion he developed grade 1 warm feeling.A 15-year-old girl, who had B-cell lymphoma received 6 doses (1 st at standard rate and 5 at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion she developed grade 1 headache.A 16-year-old boy, who had B-cell lymphoma received 3 doses (First 2 at standard rate and 3 rd at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion he developed grade 1 rash.A 3-year-old boy, who had cutaneous graft versus host (GVH) with hypereosinophilia received 4 doses (1 st at standard rate and 3 at rapid infusion rate) of rituximab 375 mg/m 2 . After second infusion he developed grade 1 hypotension.A 4-year-old girl, who had cutaneous graft versus host received 4 doses (First 3 at standard rate and 4 th at rapid infusion rate)of rituximab 375 mg/m 2 . After first infusion she developed grade 1 abdominal pain.A 14-year-old boy, who had autoimmune narcolepsia received 4 doses (First 2 at standard rate and remaining 2 at rapid infusion rate) of rituximab 375 mg/m2. After first infusion he developed grade 1 headache.A 5-year-old girl, who had Guillain-Barre or acute motor axonal neuropathy (AMAN) received 4 doses (First 2 at standard rate and remaining 2 at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion she developed grade 2 pruritus, rash and diffuse pain.A 18-year-old girl, who had myasthenia gravis received 4 doses (First 2 at standard rate and remaining 2 at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion she developed grade 2 thoracic oppression.A 23-year-old woman, who had autoimmune haemolytic anaemia received 4 doses (First 2 at standard rate and remaining 2 at rapid infusion rate) of rituximab 375 mg/m 2 . After first infusion she developed grade 2 trouble breathing.A 5-year-old boy, who had opsoclonus-myoclonus syndrome received rituximab 375 mg/m 2 . After first infusion he developed thoracic oppression and difficulty to breath and became clinically unstable. he was discontinued rapid infusion protocol.A 0.6-year-old girl, who had immunomodulation in pompe disease received rituximab 230 mg/m 2 . At first infusion she developed shivering and became clinically unstable. She was discontinued rapid infusion protocol.Author comment: "We report here a 2.7% incidence of IRR with children treated for both malignant and nonmalignant diseases." Legeay C, et al. Rapid infusion of rituximab in a heterogenous pediatric population: Safety and feasibility. Journal of Pediatric Hematology/Oncology 38: 83-85, No. 1, Jan 2016. Available from: URL: http://doi.

show abstract

Rapid Infusion of Rituximab in a Heterogenous Pediatric Population

Cited by 3 publications

References 2 publications

Rapid-Infusion Rituximab in a Pediatric Population

Rapid-Infusion Rituximab in a Pediatric Population

Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders

Rituximab

Contact Info

Product

Resources

About